Centanafadine ( free base )
Centanafadine (free base) is a dual norepinephrine-dopamine transporter inhibitor used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
For research use only. We do not sell to patients.
Chemical Information
| Name | Centanafadine ( free base ) |
|---|---|
| Iupac Chemical Name | 3-Azabicyclo(3.1.0)hexane, 1-(2-naphthalenyl)-, (1R,5S)- |
| Synonyms | Centanafadine ; EB1020 ; EB-1020 ; EB 1020 |
| Molecular Formula | C15H15N |
| Molecular Weight | 209.29 |
| Smile | [H][C@@]12CNC[C@]1(C3=CC=C4C=CC=CC4=C3)C2 |
| InChiKey | HKHCSWPSUSWGLI-CABCVRRESA-N |
| InChi | InChI=1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1 |
| CAS Number | 924012-43-1 |
| Related CAS | 923981-14-0 ( HCl Salt ) |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white Solid |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | Avoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation. |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Schoretsanitis G, de Leon J, Eap CB, Kane JM, Paulzen M. Clinically Significant Drug-Drug Interactions with Agents for Attention- Deficit/Hyperactivity Disorder. CNS Drugs. 2019 Dec;33(12):1201-1222. doi: 10.1007/s40263-019-00683-7. PMID: 31776871.
2: Nageye F, Cortese S. Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD. Expert Rev Neurother. 2019 Jul;19(7):707-717. doi: 10.1080/14737175.2019.1628640. Epub 2019 Jun 26. PMID: 31167583.
3: Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE. Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies. Neuropsychiatr Dis Treat. 2020 Jun 8;16:1411-1426. doi: 10.2147/NDT.S242084. PMID: 32606695; PMCID: PMC7292254.
Chemical Structure
_924012-43-1.png)